ProCE Banner Activity

2023 World Conference on Lung Cancer Preview: Experts Choose the Top Abstracts

Conference Coverage
Clinical Thought

Lung cancer experts highlight key studies to look for at the 2023 World Conference on Lung Cancer. CCO’s Independent Conference Coverage will include timely capsule summary slidesets of these studies and expert analysis of how they will affect lung cancer care.

Released: August 30, 2023

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Professor of Medicine
Medical Director
Thoracic Medical Oncology
University of California
San Francisco, California 

Helena Yu

Helena Yu, MD

Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Professor of Medicine
Medical Director
Thoracic Medical Oncology
University of California
San Francisco, California 

Matthew Gubens, MD, MS: consultant/advisor/speaker: AnHeart, AstraZeneca, Atreca, Cardinal Health, Genentech/Roche, Genzyme, Gilead, Guardant, Invitae, iTeos, Merus, Sanofi, Summit, Surface; researcher (paid to institution): Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Trizell.

Helena Yu, MD

Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Black Diamond, Blueprint Medicine, Cullinan Oncology, Daiichi Sankyo, Systimmune, Taiho Oncology; researcher: AstraZeneca, Black Diamond, Cullinan Oncology, Daiichi Sankyo, ERASCA, Pfizer.